The company aims to accelerate R&D in both drug discovery and materials design by providing its technology platform.

The platform was used in the discovery of two cancer drugs - Tibsovo (ivosidenib) from Agios Pharmaceuticals and Idhifa (enasidenib), now marketed by Agios and Celgene - that have been approved by the US Food and Drug Administration.

Schrödinger has built a  pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.

Founded in 1990, the company has nearly 400 employees in its New York City headquarters and around the world.